{"id":14,"date":"2018-08-09T10:02:17","date_gmt":"2018-08-09T16:02:17","guid":{"rendered":"https:\/\/sites.psych.ualberta.ca\/SynAD\/?page_id=14"},"modified":"2020-09-25T10:09:50","modified_gmt":"2020-09-25T16:09:50","slug":"who-is-synad","status":"publish","type":"page","link":"https:\/\/sites.psych.ualberta.ca\/SynAD\/who-is-synad\/","title":{"rendered":"Who is SynAD?"},"content":{"rendered":"

SynAD Executive Committee<\/strong><\/span><\/h2>\n

\"\"Alzheimer\u2019s disease is increasingly understood as a multifactorial disease of insidious onset, with influences including biological, medical, genetic, environmental, and lifestyle factors interacting across decades of the human life span. ADRD, by definition, is even broader in origins, trajectories and clinical outcomes. SynAD is committed to the proposition that much ADRD research can achieve a deeper scientific impact and broader public application when it is collaborative and perhaps especially when innovative research questions can advance rapidly or drive novel cross-pillar investigations. The SynAD executive committee is uniquely positioned to engage the broader University of Alberta ADRD community in research and community activities that accelerate traditional research or bridge the traditional pillars of research.<\/span><\/p>\n

The committee is distributed across multiple departments and faculties at the University of Alberta and are all active members of our institutional partner, the Neuroscience and Mental Health Institute <\/strong>(NMHI Director: Dr. Doug Zochodne), including the special emphasis panel on Alzheimer\u2019s, Dementia, and Prion Disease<\/em>.<\/span><\/p>\n

SynAD is also integrated provincially and nationally. Provincially, SynAD executive committee members are involved in such broader initiatives as Campus Alberta Neuroscience<\/strong> (Dr. Jack Jhamandas is Chair of CAN). Nationally, some SynAD executive committee members are among the leaders of such organizations as Canadian Consortium on Neurodegeneration in Aging <\/strong>(CCNA, Drs. Roger Dixon and Richard Camicioli are among the Leaders of CCNA) and the Brain Canada Research Program for the Identification of Ganglioside Biomarkers and Neuroprotective Mechanisms in Huntington\u2019s Disease <\/strong>(Dr. Simonetta Sipione is Lead PI).<\/span><\/p>\n

Professionally, the SynAD committee is actively engaged in research in complementary aspects of ADRD, including brain aging, mild cognitive or motor impairment, Alzheimer\u2019s, Parkinson\u2019s, Huntington\u2019s, and prion diseases. \u00a0We have a well-grounded home base in NMHI and a promising collaborative foundation, with numerous joint research projects and publications, but our goal is to expand beyond the current committee to include many other colleagues in NMHI.<\/span><\/p>\n

The following list introduces the current SynAD Executive Committee.<\/span><\/p>\n

<\/h3>\n

Principal Investigator<\/strong><\/span><\/h3>\n

\"\"Roger A. Dixon, PhD<\/strong><\/span>
\nProfessor of Psychology (Science)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/sites.ualberta.ca\/~vlslab\/DixonHomepage\/index.html<\/a>
\nExample Publication<\/span>: Badhwar A, McFall GP, Sapkota S, Black S, Chertkow H, Duchesne S, Masellis M, Li L, Dixon RA, Bellec P. A multiomics approach to heterogeneity in Alzheimer’s disease: Focused review and roadmap. Brain 2020;143<\/span>(5):1315-1331.<\/span>\u00a0<\/span>doi:10.1093\/brain\/awz384<\/span><\/p>\n


\nCo-Principal Investigators<\/strong><\/span><\/h3>\n

\"\"Jack Jhamandas, MD, PhD<\/strong><\/span>
\nDistinguished Professor of Medicine (Neurology, FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/medicine\/about\/people\/jack-h-jhamandas<\/a>
\nExample Publication<\/span>: Soudy R, Patel A, Fu W, Kaur K, MacTavish D, Westaway D, Davey R, Zajac J, Jhamandas J. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer’s disease. Alzheimer’s & Dementia (N Y) 2016;3(1):44-56. doi:10.1016\/j.trci.2016.11.005<\/span><\/p>\n

Satyabrata Kar, PhD<\/strong>\"\"<\/strong><\/span>
\nProfessor of Psychiatry (FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/faculties\/centresinstitutes\/prion-centre\/faculty-and-staff\/satyabrata-kar<\/a>
\nExample Publication<\/span>: Kodam A, Ourdev D, Maulik M, Hariharakrishnan J, Banerjee M, Wang Y, Kar S. A role for astrocyte-derived amyloid \u03b2 peptides in the degeneration of neurons in an animal model of Temporal Lobe Epilepsy. Brain Pathology 2018 (in press).\u00a0<\/span>doi:10.1111\/bpa.12617\u00a0<\/span><\/p>\n


\nSimonetta Sipione, PhD<\/strong>\"\"<\/strong><\/span>
\nAssociate Professor of Pharmacology (FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/pharmacology\/people\/faculty\/sipione-detail<\/a>
\nExample Publication<\/span>: Alpaugh M, Galleguillos D, Forero J, Morales LC, Lackey SW, Kar P, Di Pardo A, Holt A, Kerr B, Todd KG, Baker GB, Fouad K, Sipione S. Disease-modifying effects of ganglioside GM1 in Huntington\u2019s disease models. EMBO Molecular Medicine\u00a02017;9(11):1537-1557. doi:10.15252\/emmm.201707763<\/span><\/p>\n

David Westaway, PhD<\/strong>\"\"<\/strong><\/span>
\nDirector, Centre for Prions and Protein Folding Diseases<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/prion-centre\/faculty-and-staff\/david-westaway.html<\/a>
\nExample Publication<\/span>:\u00a0Eskandari-Sendighi G, Daude N, Gapeshina H, Sanders DW, Kamali-Jamil R, Yang J, Shi B, Wille H, Ghetti B, Diamond MI, Janus C, Westaway D. The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition. Molecular Neurodegeneration 2017;12(1):72. doi:10.1186\/s13024-017-0215-7<\/span><\/p>\n


\nCo-Investigators<\/strong><\/span><\/h3>\n

Richard Camicioli, MD<\/strong>\"\"<\/strong><\/span>
\nProfessor of Medicine (Neurology, FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/medicine\/about\/people\/richard-camicioli<\/a>
\nExample Publication<\/span>:\u00a0Montero-Odasso M, Sarquis-Adamson Y, Speechley M, Muir-Hunter S, Sposato L, Wells J, Borrie M, Camicioli R. “Gait and Cognition syndrome” and the risk of dementia in the Gait & Brain Study. Alzheimer’s & Dementia (N Y) 2017;13(7):P577. doi:10.1016\/j.jalz.2017.07.199<\/span><\/p>\n


\nElena Posse de Chaves, PhD<\/strong>\"\"<\/strong><\/span>
\nProfessor of Pharmacology (FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/www.ualberta.ca\/pharmacology\/people\/faculty\/possedechaves-detail<\/a>
\nExample Publication<\/span>:\u00a0Mohamed A, Viveiros A, Williams K, Posse de Chaves E. Abeta inhibits SREBP-2 activation through Akt inhibition.
\nJournal of Lipid Research 2018;59:1-13. doi:10.1194\/jlr.M076703
\n<\/span><\/p>\n


\nValerie Sim, MD<\/strong>\"\"<\/strong><\/span>
\nAssociate Professor of Medicine (Neurology, FoMD)<\/span>
\nWebsite<\/span>:<\/span>\u00a0https:\/\/sites.ualberta.ca\/~vsim\/<\/a>
\nExample Publication<\/span>: Norman G, Campeau J, Sim VL. High dose and delayed treatment with bile acids ineffective in RML prion-infected mice. Antimicrobial Agents and Chemotherapy 2018;62(8):e00222-18. doi:10.1128\/AAC.00222-18<\/span><\/p>\n

<\/h3>\n


\nSynAD Coordinator<\/strong><\/span><\/h3>\n

Jill Friesen<\/strong><\/span>
\nContact<\/span>: SynAD@ualberta.ca<\/span><\/p>\n\n\n\n\n\t

Contact SynAD: How to Get Involved<\/strong><\/span><\/h3>SynAD is open for expressions of interest from all members (Faculty and Post Doctoral Fellows) of NMHI who are part of ADRD research and practice community at the University of Alberta. Specifically, the SynAD program has three initiatives which will provide funding opportunities for ADRD research. These include small catalyst grants for equipment acquisition, trainee support, and research support.
\n
\nIn the future, we will be developing a SynAD Members\/Researchers list and SynAD Trainees list. We will be holding NMHI-wide events, larger University of Alberta group information meetings, and broader public representations.
\n
\nThe contact email for SynAD is SynAD@ualberta.ca<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"

SynAD Executive Committee Alzheimer\u2019s disease is increasingly understood as a multifactorial disease of insidious onset, with influences including biological, medical, genetic, environmental, and lifestyle factors interacting across decades of the human life span. ADRD, by definition, is even broader in origins, trajectories and clinical outcomes. SynAD is committed to the proposition that much ADRD research…<\/p>\n

Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-14","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/pages\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/comments?post=14"}],"version-history":[{"count":41,"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/pages\/14\/revisions"}],"predecessor-version":[{"id":792,"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/pages\/14\/revisions\/792"}],"wp:attachment":[{"href":"https:\/\/sites.psych.ualberta.ca\/SynAD\/wp-json\/wp\/v2\/media?parent=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}